Document is current
Any future updates will be listed below
-
Authors
Judge, Daniel P. https://orcid.org/0000-0002-3407-0248
Udall, Margarita
Rosen, Andrew M.
Lamarre, Neil
Nagelhout, Elizabeth
Dao, Hanh Dung
Maurer, Mathew S.
-
Funding
Funding for this research was provided by:
BridgeBio Pharma, Inc.
- License Information
-
More Information
Article History
Received: 7 October 2025
Accepted: 27 November 2025
First Online: 19 December 2025
Declarations
:
: Daniel P. Judge: Consultancy fees from Alnylam Pharmaceuticals, Attralus, Bayer, BridgeBio Pharma, Inc., Cytokinetics, Lexeo Therapeutics, Novo Nordisk, Rocket Pharmaceuticals, and Tenaya Therapeutics. Margarita Udall and Andrew M. Rosen: Employees and stockholders of BridgeBio Pharma, Inc. Margarita Udall is a stockholder of Pfizer, Inc. Neil Lamarre, Elizabeth Nagelhout, and Hanh Dung Dao: Contractors for BridgeBio Pharma, Inc. Mathew S. Maurer: for NIH R01HL139671 and R01AG081582-01, Alnylam Pharmaceuticals, BridgeBio Pharma, Inc. (formerly Eidos Therapeutics), Ionis Pharmaceuticals, Pfizer Inc., and Prothena Biosciences; consultant or advisor for Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, Attralus, BridgeBio Pharma, Inc. (formerly Eidos Therapeutics), Intellia Therapeutics, Ionis Pharmaceuticals, Novo Nordisk, and Pfizer, Inc.
: Because the Komodo Healthcare Map database contains anonymized, de-identified data that complies with the Health Insurance Portability and Accountability Act, and this study did not involve the collection, use, or transmittal of individually identifiable data, the study did not require ethics committee review or informed consent. Permission was obtained to access and analyze data.
